Esophageal carcinoma (squamous + adeno) · line 1 · Weekly carboplatin + paclitaxel (CROSS-style chemo backbone)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Ligne thérapeutique | 1 |
|---|---|
| Voie | standard |
| Régime lié | REG-CARBOPLATIN-PACLITAXEL-WEEKLY |
| ID | IND-ESOPH-RESECTABLE-CROSS-NEOADJUVANT |
|---|---|
| Type | Indication |
| État | reviewed 2026-05-08 | pending_clinical_signoff |
| Maladies | DIS-ESOPHAGEAL |
| Sources | SRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 |
Notes
§17 phased indication (RATIFIED 2026-05-07). Free-text RT description in this `notes:` block has been replaced by structured `phases:` field with radiation_id=RC-CROSS-NEOADJ; the RadiationCourse owns the concurrent chemo regimen reference (concurrent_chemo_regimen=REG-CARBOPLATIN-PACLITAXEL-WEEKLY) per planning doc §2.3 (XOR rule on phase fields). The post-CROSS surgery phase (esophagectomy) is deferred to C4 chunk (#437) — this entity models the neoadjuvant CRT phase only. Backward-compat: legacy `recommended_regimen=REG-CARBOPLATIN-PACLITAXEL-WEEKLY` preserved so non-§17-aware render paths continue to surface the chemo backbone. Adjuvant nivolumab post-resection (CheckMate-577, ypT+ or ypN+) is a separate downstream indication and remains out of scope for this chunk.
Utilisé par
Algorithmes
ALGO-ESOPH-RESECTABLE-1L- ALGO-ESOPH-RESECTABLE-1L
Indication
IND-ESOPH-ADJUVANT-NIVOLUMAB-POST-CROSS- IND-ESOPH-ADJUVANT-NIVOLUMAB-POST-CROSSIERIND-RECTAL-TNT-LONG-COURSE-PRODIGE23- IND-RECTAL-TNT-LONG-COURSE-PRODIGE23IND-RECTAL-TNT-SHORT-COURSE-RAPIDO- IND-RECTAL-TNT-SHORT-COURSE-RAPIDO